MEC Dynamics Corp (MEC) announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its new point-of-care (PoC) test, the Avie A1c, for the quantitative measurement of HbA1c in diabetic patients. MEC’s Avie A1c is the first in its range of rapid PoC tests that will use its patented platform to offer high performance and affordable diagnostics for the physician’s office as well as home testing. Avie A1c has many features designed to deliver quick and accurate results for HbA1c. Using blood from a finger prick and a single use disposable cartridge, HbA1c results are displayed on the screen of the handheld reader within 3 minutes. The Avie A1c is NGSP certified for accuracy. Features of MEC’s Avie A1c include: • 3 minute HbA1c test with blood from finger prick • No sample preparation, venesection or centrifugation • Low cost handheld colorimetric reader with screen • Connectivity to ancillary printer • Inexpensive and accurate measurement • Electronically coded cartridges • Convenient for home or clinic use • Optional customizable data management software Key facets of the Avie A1c system are its ease of use, its low cost compact reader as well as its software that allows for accurate and quick results. "As the trend towards diagnostics taking place in the physician’s office and in the home accelerates, MEC’s first FDA approved point-of-care product, Avie A1c, offers a simple, affordable and accurate device for the monitoring of patients with diabetes" said Manny Mpock, CEO, MEC Dynamics Corp.